Back to journals
Academic Journal

Psychopharmacology

110 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 110 psychedelic papers Blossom tracks from Psychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Psychopharmacology carry?

Sourced

Tracked papers by publication year; 11 earlier papers published before 2012. Click a year for the running total.

12papers published in 2017

+300% vs 2016

42 published by 2017

Browse papers→

Don't read as the journal's total output: only the 110 of 110 tracked psychedelic papers from Psychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Psychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
41
Anxiety Disorders
33
Addiction & Substance Use
24
Neuroimaging & Brain Measures
16
PTSD
13
Personality & Trait Factors
12
Interpersonal Functioning & Social Connectedness
11
Schizophrenia
10
Other
86

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Psychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
34
LSD
25
Ayahuasca
19
MDMA
19
Ketamine
12
DMT
4
5-MeO-DMT
3
Mescaline
2
Other
6

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Psychopharmacology has 110 tracked papers indexed in Blossom (1995–2026) from 542 authors, most often covering Psilocybin, LSD and Ayahuasca, across Depressive Disorders, Healthy Volunteers and Anxiety Disorders.

Published Papers

Open Accessindividual

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers

This subgroup reanalysis of a RCT (n=28) in healthy men found that a combined DMT and harmine formulation reduced embarrassment and shame when participants evaluated their own singing, whereas harmine alone did not. The effect was seen only for self-related negative emotions and not for other vocal recordings.

Published
Journal
Psychopharmacology
Authors
Aicher, H. D., Dornbierer, J., Caflisch, L., Suay, D., Mueller, M. J., Landolt, H.-P., Quednow, B. B., Scheidegger, M., Dornbierer, D.
Open Accessindividual

Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study

This reanalysis of an RCT (n=53) of adults with ADHD tested repeated low-dose LSD (20 µg) over six weeks and found no broad improvement in attention, inhibition or motivation. The only effect observed was on one measure of temporal processing, and it did not align with improvements in clinical symptoms.

Published
Journal
Psychopharmacology
Authors
Haijen-Bongers, E. C. H. M., Hurks, P. P. M., Schepers, J., Vizeli, P., Santos de Jesus, J., Mueller, L., Schmid, Y., Liechti, M. E., Kuypers, K. P. C.
Open Accessindividual

Psilocybin's kinematic effect on manual dexterity

This randomised blinded trial (n=healthy participants) tested low to moderate doses of psilocybin (5 to 20 mg) and found only small, short-lived changes in manual dexterity, with no meaningful disruption to hand movement smoothness, speed or coordination structure. Higher doses caused slight impairment at peak effect and slight improvement later, suggesting psilocybin may be compatible with motor rehabilitation.

Published
Journal
Psychopharmacology
Authors
Klintefors, P., Bhagavan, C., Kanaan, R., Bryson, A., Berlowitz, D., Attard, Z., Carter, O.
Open Accessmeta

Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study

This mixed-method study (n=112) explored attitudes towards psychedelic therapy among people with alcohol use disorder and found that most were aware of psychedelic research and many were willing to join a trial, especially if they expected it to work. Interviews showed views ranged from positive to negative, shaped by hopes of benefit, fears about addiction or losing control, and media exposure.

Published
Journal
Psychopharmacology
Authors
Kirsch, J., Poppe, C., Beck, A., Brabeck, A., Gutwinski, S., Lütt, A., Rosenthal, A., Tsamitros, N., Repantis, D.
Open Accessindividual

Psilocybin-induced neurocardiogenic syncope: a case report

This case report describes a healthy 35-year-old man who fainted after taking 25 mg oral psilocybin during an open-label brain function study, with low blood pressure, rapid heartbeat and sweating consistent with neurocardiogenic syncope. He recovered quickly with simple supportive care, highlighting a rare hypotensive reaction during psilocybin administration.

Published
Journal
Psychopharmacology
Authors
Atiq, M. A., Weisman, E., Guerra, R. B., Martinez, L. L., Yaden, D. B., Barrett, F. S., Nayak, S., Sayali, C.
Open Accessmeta

Evaluating the evidence for repressed memory recovery in psychedelic contexts

This scoping review (s=53) examined reports of repressed memory recovery in psychedelic contexts and found that most of the literature focused on LSD, with little agreement on what repressed memory means. It found only limited evidence for proposed psychological or brain-based explanations, and no consistent proof that psychedelics reliably recover repressed memories.

Published
Journal
Psychopharmacology
Authors
Griesfeller, A. F., Kooman, L., Kloft-Heller, L., Kangaslampi, S., Ramaekers, J. G., Otgaar, H.

Quick Facts

Papers Indexed
110
h-Index
218
Open Access
No
Publisher
Springer Nature
Country
Germany
Website
Visit